These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 21404136)

  • 1. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
    Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
    Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
    Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
    J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
    Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
    Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between FDG uptake and apparent diffusion coefficients in glioma and malignant lymphoma.
    Matsushima N; Maeda M; Umino M; Suzawa N; Yamada T; Takeda K
    Ann Nucl Med; 2012 Apr; 26(3):262-71. PubMed ID: 22311413
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Kong Z; Jiang C; Zhu R; Feng S; Wang Y; Li J; Chen W; Liu P; Zhao D; Ma W; Wang Y; Cheng X
    Neuroimage Clin; 2019; 23():101912. PubMed ID: 31491820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation between Glioblastoma Multiforme and Primary Cerebral Lymphoma: Additional Benefits of Quantitative Diffusion-Weighted MR Imaging.
    Ko CC; Tai MH; Li CF; Chen TY; Chen JH; Shu G; Kuo YT; Lee YC
    PLoS One; 2016; 11(9):e0162565. PubMed ID: 27631626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
    You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
    Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Imaging; 2015; 39(3):390-5. PubMed ID: 25547624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
    Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
    Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach.
    Suh HB; Choi YS; Bae S; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2018 Sep; 28(9):3832-3839. PubMed ID: 29626238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
    Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
    World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
    Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
    J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.